Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1429516

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1429516

Insulin Drugs Global Market Report 2024

Published: Pre-Order
PAGES: 175 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

Insulin drugs are medications prescribed for the treatment of diabetes, encompassing both type 1 diabetes and type 2 diabetes mellitus. These drugs come in various types, preparations, and dosage amounts. Insulin, a hormone naturally produced in the body, plays a crucial role in facilitating the uptake of glucose (sugar) by cells throughout the body, converting it into a form usable for energy.

The primary product types of insulin drugs include basal or long-acting insulins, bolus or fast-acting insulins, pre-mixed insulins, and intermediate and short-acting insulins. Basal or long-acting insulins are utilized in diabetes management to provide a slow, steady release of insulin throughout the day and night. Insulin source types include insulin analogs and human insulin, while drugs are categorized into branded and generic drugs, distributed through hospital pharmacies, retail pharmacies, and online platforms. The various applications of insulin drugs encompass type II diabetes, type I diabetes, and gestational diabetes.

The insulin drugs market research report is one of a series of new reports from The Business Research Company that provides insulin drugs market statistics, including insulin drugs industry global market size, regional shares, competitors with an insulin drugs market share, detailed insulin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the insulin drugs industry. This insulin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The insulin drugs market size has grown rapidly in recent years. It will grow from $31.09 billion in 2023 to $34.6 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The expansion observed in the historical period can be attributed to factors such as the increase in diabetes prevalence, growth in emerging markets, an increased geriatric population, and the growth in the use of insulin analogues.

The insulin drugs market size is expected to see rapid growth in the next few years. It will grow to $51.81 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The anticipated growth in the forecast period can be attributed to factors such as the increase in disease burden, government initiatives, and a rise in research and development (R&D) activities along with collaborations. Significant trends expected in the forecast period include the launch of new products to enhance product offerings, the expansion of product portfolios and businesses through mergers and acquisitions, the adoption of strategic partnerships to promote product offerings, increased investments in research and development for the development of new insulin delivery methods, and the investment in advanced solutions to reduce R&D costs and accelerate development timelines.

The increasing prevalence of diabetes, driven by changing lifestyles marked by long working hours, reduced physical activity, and unhealthy eating habits, is anticipated to boost the demand for diabetes drugs in the forecast period. Sedentary lifestyles have been linked to a higher incidence of diabetes, and individuals suffering from obesity face up to an 80-fold increased risk of developing type 2 diabetes. Projections from the World Health Organization (WHO) indicate a concerning trend, with an expected 74% of men and 64% of women in the UK being overweight by 2030. This surge in diabetes cases is likely to propel the diabetes therapies market.

The insulin drugs market is poised for growth due to the rising prevalence of obesity, a known risk factor for diabetes. Obesity, characterized by excess body fat adversely affecting health, is closely linked to diabetes development. Insulin drugs, used in the context of obesity, can contribute to weight gain, exacerbating the obesity issue. In England, for instance, projections from the Government Digital Service indicate a 25.2% increase in obesity among individuals aged 18 and older in the period 2021-2022. The escalating rates of obesity are a key driver for the growth of the insulin drugs market.

A discernible trend in the insulin market is the increasing number of mergers and acquisitions focused on developing new formulations. Companies are actively investing in innovative medicines for diabetes treatment. Researchers at Lund University Diabetes Centre utilized CRISPR, a genome modification tool, to turn off genes responsible for diabetes, resulting in increased insulin production and decreased beta cell death. Novo Nordisk has developed a diabetes pill based on glucagon-such as peptide-1 (GLP-1s) that stimulates insulin production, anticipating significant annual sales.

Major companies in the insulin drugs market are emphasizing product innovation, exemplified by the introduction of the triple fixed-dose combination (FDC) of teneligliptin with pioglitazone and metformin. Glenmark Pharmaceuticals Limited, an Indian pharmaceutical company, launched Zita-PioMet, a triple FDC for treating type 2 diabetes and high insulin resistance. This innovation aims to improve glycemic control in adults with uncontrolled diabetes despite other treatments.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical company, acquired Protomer Technologies Inc. for $1 billion. This acquisition enhances Lilly's capabilities in insulin therapy advancements, particularly in developing glucose-sensing insulin. Protomer Technologies, a pre-clinical stage biotechnology company, specializes in research and technology development for metabolic disorders, aligning with Lilly's commitment to improving the lives of diabetes patients.

Major companies operating in the insulin drugs market report are Novo Nordisk, Sanofi S.A., Eli Lilly And Company, Biocon Ltd., and Gan & Lee Pharmaceuticals, Bioton, Wockhardt Ltd., Julphar, Tonghua Dongbao Pharmaceutical, AstraZeneca, Mehar healthcare, GE Healthcare, Philips Healthcare India, Shandong WeiGao Group Medical Polymer Company Limited, Yuwell Medical Equipment & Supply Co, Terumo, NIPRO, Olympus Medical Systems, Hitachi Medico, Nihon Kohden, Fukuda Denshi, Emperra GmbH E-Health Technologies, DIABNEXT™, Berlin-Chemie AG, Ypsomed Holding AG, Patients Pending Ltd., Dexcom, Johnson and Johnson, Medtronic, Abbott Laboratories, Acon Laboratories, Ypsomed AG, Tandem Diabetes Care, Inc., Becton, Dickinson, Insulet Corporation, AJA Pharma, SEDICO Pharmaceutical Company, Pfizer

North America was the largest region in the insulin drugs market in 2023. The Middle East is expected to be the largest growing region in the global insulin drugs market share during the forecast period. The regions covered in the insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the insulin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The insulin drugs market consists of sales of rapid-acting insulin, short-acting insulin, and mixed insulin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Insulin Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on insulin drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for insulin drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The insulin drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product Type: Basal Or Long-Acting Insulins; Bolus Or Fast-Acting Insulins; Pre-Mixed; And Intermediate And Short Acting Insulins
  • 2) By Source Type: Insulin Analogs; And Human Insulin
  • 4) By Drug Classification: Branded Drugs, And Generic Drugs
  • 3) By Application: Type 2 Diabetes; Type 1 Diabetes; And Gestational Diabetes
  • 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; And Online
  • Companies Mentioned: Novo Nordisk; Sanofi S.A.; Eli Lilly And Company; Biocon Ltd; and Gan & Lee Pharmaceuticals
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.
Product Code: r14487

Table of Contents

1. Executive Summary

2. Insulin Drugs Market Characteristics

3. Insulin Drugs Market Trends And Strategies

4. Insulin Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Insulin Drugs Market Size and Growth

  • 5.1. Global Insulin Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Insulin Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Insulin Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Insulin Drugs Market Segmentation

  • 6.1. Global Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Basal Or Long-Acting Insulins
  • Bolus Or Fast-Acting Insulins
  • Pre-Mixed
  • Intermediate And Short Acting Insulins
  • 6.2. Global Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Insulin Analogs
  • Human Insulin
  • 6.3. Global Insulin Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Branded Drugs
  • Generic Drugs
  • 6.4. Global Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Gestational Diabetes
  • 6.5. Global Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

7. Insulin Drugs Market Regional And Country Analysis

  • 7.1. Global Insulin Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Insulin Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Insulin Drugs Market

  • 8.1. Asia-Pacific Insulin Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Insulin Drugs Market

  • 9.1. China Insulin Drugs Market Overview
  • 9.2. China Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Insulin Drugs Market

  • 10.1. India Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Insulin Drugs Market

  • 11.1. Japan Insulin Drugs Market Overview
  • 11.2. Japan Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Insulin Drugs Market

  • 12.1. Australia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Insulin Drugs Market

  • 13.1. Indonesia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Insulin Drugs Market

  • 14.1. South Korea Insulin Drugs Market Overview
  • 14.2. South Korea Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Insulin Drugs Market

  • 15.1. Western Europe Insulin Drugs Market Overview
  • 15.2. Western Europe Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Insulin Drugs Market

  • 16.1. UK Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Insulin Drugs Market

  • 17.1. Germany Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Insulin Drugs Market

  • 18.1. France Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Insulin Drugs Market

  • 19.1. Italy Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Insulin Drugs Market

  • 20.1. Spain Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Insulin Drugs Market

  • 21.1. Eastern Europe Insulin Drugs Market Overview
  • 21.2. Eastern Europe Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Insulin Drugs Market

  • 22.1. Russia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Insulin Drugs Market

  • 23.1. North America Insulin Drugs Market Overview
  • 23.2. North America Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Insulin Drugs Market

  • 24.1. USA Insulin Drugs Market Overview
  • 24.2. USA Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Insulin Drugs Market

  • 25.1. Canada Insulin Drugs Market Overview
  • 25.2. Canada Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Insulin Drugs Market

  • 26.1. South America Insulin Drugs Market Overview
  • 26.2. South America Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Insulin Drugs Market

  • 27.1. Brazil Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Insulin Drugs Market

  • 28.1. Middle East Insulin Drugs Market Overview
  • 28.2. Middle East Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Insulin Drugs Market

  • 29.1. Africa Insulin Drugs Market Overview
  • 29.2. Africa Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Insulin Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Insulin Drugs Market Competitive Landscape
  • 30.2. Insulin Drugs Market Company Profiles
    • 30.2.1. Novo Nordisk
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Sanofi S.A.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Eli Lilly And Company
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Biocon Ltd
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. and Gan & Lee Pharmaceuticals
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Insulin Drugs Market Other Major And Innovative Companies

  • 31.1. Bioton
  • 31.2. Wockhardt Ltd
  • 31.3. Julphar
  • 31.4. Tonghua Dongbao Pharmaceutical
  • 31.5. AstraZeneca
  • 31.6. Mehar healthcare
  • 31.7. GE Healthcare
  • 31.8. Philips Healthcare India
  • 31.9. Shandong WeiGao Group Medical Polymer Company Limited
  • 31.10. Yuwell Medical Equipment & Supply Co
  • 31.11. Terumo
  • 31.12. NIPRO
  • 31.13. Olympus Medical Systems
  • 31.14. Hitachi Medico
  • 31.15. Nihon Kohden

32. Global Insulin Drugs Market Competitive Benchmarking

33. Global Insulin Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Insulin Drugs Market

35. Insulin Drugs Market Future Outlook and Potential Analysis

  • 35.1 Insulin Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Insulin Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Insulin Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!